English Abstract
Journal Article
Add like
Add dislike
Add to saved papers

[Over-expression of prohibitin gene promotes apoptosis in retinoic acid-resistant acute promyelocytic leukemia cell line NB4-R1].

OBJECTIVE: To construct a eukaryotic expression vector carrying human prohibitin gene and study the effect of prohibitin over-expression on the apoptosis of retinoic acid-resistant acute promyelocytic leukemia NB4-R1 cells.

METHODS: The prohibitin gene was amplified by PCR, and then cloned into pEGFP-N1-3FLAG eukaryotic expression vector. Positive clones were selected by PCR screening and identified by DNA sequencing. The positive recombinant vector pEGFP-N1-3FLAG-prohibitin was transferred into NB4-R1 cells. The over-expression of prohibitin was verified by real-time PCR and Western blotting, respectively. The apoptosis rate of the NB4-R1 cells transfected with pEGFP-N1-3FLAG-prohibitin was measured by flow cytometry combined with annexin V-FITC/PI staining.

RESULTS: PCR screening and DNA sequencing demonstrated that the recombinant plasmid of pEGFP-N1-3FLAG-prohibitin was constructed successfully; and the transfection efficiency of NB4-R1 cells reached more than 70%. Moreover, qRT-PCR showed that the expression of prohibitin mRNA of transfection group (OE) increased by (1.64±0.37) times and (1.58±0.43) times (P<0.05) compared with blank control group (CON) and negative control group (NC), respectively. Western blotting showed that the expression of prohibitin protein of OE group increased by (1.91±0.33) times and (1.99±0.37) times (P<0.05) compared with CON and NC, respectively; Flow cytometry indicated that the NB4-R1 cell apoptosis rates in CON, NC and OE groups were respectively (5.88± 0.43)%, (6.63±0.46)% and (28.22±1.33)%, and the apoptosis rate of OE group was elevated by (3.80±0.24) times and 3.39± 0.30 times compared with CON and NC(P<0.05), respectively.

CONCLUSION: The up-regulated expression of prohibitin could promote NB4-R1 cell apoptosis.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app